INURA
Novel drug delivery for overactive bladder treatment.
Inura Medical AG is a Swiss-based femtech company dedicated to advancing women's health by developing new treatments for diseases of the bladder and lower urinary tract. Founded in May 2015 and based at the HEMEX incubator in Liestal, the company operates in the medtech and urology sectors.
The company's first product is a patented intraurethral ovulum designed to treat Overactive Bladder (OAB). This product offers a novel drug administration route that facilitates more effective penetration of the drug to its site of action, improving its pharmacokinetic profile while minimizing potential side effects. The technology is the result of decades of urological research by Professor S. Grant Mulholland of Jefferson Medical College, a former president of the American Urology Association.
Inura Medical's business model focuses on research and development to address unmet medical needs in women's health. The company secured pre-series A funding in May 2021 from undisclosed investors to finalize pre-clinical activities and advance business development. The leadership team includes CEO Vanja Ivancevic and CMO Rafiq Hussain.
Keywords: femtech, urology, overactive bladder, OAB, drug delivery, medical device, women's health, intraurethral ovulum, bladder disease, pharmaceutical, medtech, HEMEX incubator, Liestal, S. Grant Mulholland, Vanja Ivancevic, Rafiq Hussain